Aligos Therapeutics (ALGS) EBT Margin (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly EBT Margin came in at 802.93% in Q1 2026, down 1467142.0% YoY from N/an in Q1 2025, and up 93.16% on a QoQ basis from 11746.15% in Q4 2025.
Aligos Therapeutics (ALGS) EBT Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of EBT Margin data on file, last reported at 802.93% in Q1 2026.
- Quarterly EBT Margin fell 1467142.0% year-over-year to 802.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2263.7% (down 11024329.0% YoY) and the FY2025 annual result came in at 1092.36%, up 3809327.0% from the prior year.
- EBT Margin advanced to 802.93% in Q1 2026, from 11746.15% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 13868.49% in Q1 2025 to a low of 16368.57% in Q1 2023.
- A 5-year average of 1418.61% and a median of 802.93% in 2026 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin tumbled 1498537 bps — and 2025, when it surged 1888852 bps.
- Tracing ALGS's EBT Margin over 5 years: stood at 157.02% in 2022, then surged by 1663 bps to 2453.6% in 2023, then rose by 25 bps to 3074.62% in 2024, then slumped by 482 bps to 11746.15% in 2025, then soared by 93 bps to 802.93% in 2026.
- The last three EBT Margin figures came in at 802.93% (Q1 2026), 11746.15% (Q4 2025), and 1624.66% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -802.93% |
| Dec 31, 2025 | -11,746.15% |
| Jun 30, 2025 | -1,624.66% |
| Mar 31, 2025 | 13,868.49% |
| Dec 31, 2024 | 3,074.62% |
| Sep 30, 2024 | -1,533.44% |
| Jun 30, 2024 | 494.82% |
| Mar 31, 2024 | -5,020.03% |
| Dec 31, 2023 | 2,453.60% |
| Sep 30, 2023 | -1,660.09% |
| Jun 30, 2023 | -419.98% |
| Mar 31, 2023 | -16,368.57% |
| Dec 31, 2022 | -157.02% |
| Sep 30, 2022 | -454.55% |
| Mar 31, 2022 | -1,383.20% |
| Dec 31, 2021 | -10,292.10% |
| Sep 30, 2021 | -2,146.91% |
| Jun 30, 2021 | -1,928.16% |
| Mar 31, 2021 | -3,036.15% |